Back to Search
Start Over
Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes
- Source :
- Diabetologia
- Publication Year :
- 2017
-
Abstract
- The treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss. Endotrophin, the C-terminal fragment of the α3 chain of procollagen type VI (also called Pro-C6), is involved in both adipose tissue matrix remodelling and metabolic control. We established a serum assay for endotrophin to assess if this novel adipokine could identify type 2 diabetic patients who respond optimally to PPARγ agonists, improving the risk-to-benefit ratio. The BALLET trial (NCT00515632) compared the glucose-lowering effects and safety of the partial PPARγ agonist balaglitazone with those of pioglitazone in individuals with type 2 diabetes on stable insulin therapy. The per protocol population (n = 297) was stratified into tertiles based on baseline endotrophin levels. Participants were followed-up after 26 weeks, after which correlational analysis was carried out between endotrophin levels and measures of glucose control. This is a secondary post hoc analysis. Endotrophin was significantly associated with therapeutic response to balaglitazone and pioglitazone. At week 26, only individuals in the upper two tertiles showed significant reductions in HbA1c and fasting serum glucose compared with baseline. The OR for a 1% and a 0.5% reduction in HbA1c for individuals in the upper two tertiles were 3.83 (95% CI 1.62, 9.04) p
- Subjects :
- 0301 basic medicine
Blood Glucose
Male
medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
Population
Adipose tissue
Adipokine
Type 2 diabetes
Collagen Type VI
03 medical and health sciences
0302 clinical medicine
Insulin resistance
Diabetes mellitus
Internal medicine
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Insulin
education
Aged
education.field_of_study
Pioglitazone
business.industry
Middle Aged
medicine.disease
Peptide Fragments
3. Good health
PPAR gamma
030104 developmental biology
Endocrinology
Adipose Tissue
Diabetes Mellitus, Type 2
030220 oncology & carcinogenesis
Quinazolines
Female
Thiazolidinediones
business
medicine.drug
Subjects
Details
- ISSN :
- 0012186X
- Database :
- OpenAIRE
- Journal :
- Diabetologia
- Accession number :
- edsair.doi.dedup.....099d34052cf6f4315023fbb42084d019
- Full Text :
- https://doi.org/10.1007/s00125-016-4094-1